Salmonella (e.g., Salmonella Typhimurium, Etc.) Patents (Class 424/258.1)
-
Publication number: 20110111015Abstract: Vaccines comprising TRAP polypeptides and Salmonella enteritidis vectors comprising TRAP polypeptides are provided. The vaccines may also include a CD 154 polypeptide capable of binding to CD4Q. Also provided are methods of enhancing an immune response against Apicomplexan parasites and methods of reducing morbidity associated with infection with Apicomplexan parasites.Type: ApplicationFiled: November 3, 2008Publication date: May 12, 2011Inventors: Walter Bottje, Billy Hargis, Luc Berghman, Young Min Kwon, Kimberly Cole, Mandy Cox, Sherryll Layton, Said El-Ashram, John Barta, Guillermo Tellez
-
Publication number: 20110110979Abstract: The present invention relates to a method for treating an infection or disease or lesion, in particular an HPV infection. Furthermore, it relates to a vaccine for treating a Human Papillomavirus (HPV) infection or an associated disease or lesion in a subject.Type: ApplicationFiled: April 1, 2009Publication date: May 12, 2011Applicant: Universite De LausanneInventor: Denise Nardelli Haefliger
-
Patent number: 7935355Abstract: An antigen composition for stimulating an immune response in an inoculated avian species to at least one intestinal pathogenic organism includes naturally-occurring wild Salmonella enterica subspecies in O-serogroups B, C3 and D. Subspecies in O-serogroup B can include Salmonella typhimurium and/or Salmonella agona. Subspecies in O-serogroup C3 can include Salmonella Kentucky. Subspecies in O-serogroup D can include Salmonella enteritidis. The antigen composition can be used alone or in combination with a Marek's Disease vaccine to reduce shedding of E. coli and/or Salmonella bacteria.Type: GrantFiled: February 4, 2008Date of Patent: May 3, 2011Assignee: Nutritional Health Institute Laboratories, LLCInventor: Konky Sotomayor
-
Publication number: 20110064723Abstract: This invention provides methods and compositions for stabilizing proteins and vaccines in dried formulations. In particular, a cavitation method and compositions of preparing a dried vaccine are provided that stabilize the viability of live bacteria and live virus vaccines at room temperature.Type: ApplicationFiled: September 13, 2010Publication date: March 17, 2011Inventors: Vu Truong-Le, Satoshi Ohtake, Gary Chiueh, Russell A. Martin, Atul Saxena, Binh V. Pham, David Lechuga-Ballesteros
-
Patent number: 7887816Abstract: The present invention pertains to a Salmonella microorganism having an attenuating mutation which disrupts the expression of a gene located within the Spi2 pathogenicity island, and an auxotrophic mutation. The microorganism therefore has a double mutation which helps prevent reactivity of the microorganism while maintaining the effectiveness of the microorganism to elicit an immune response. The present invention also pertains to vaccine compositions and methods for treating and preventing a Salmonella infection in a patient.Type: GrantFiled: February 1, 2007Date of Patent: February 15, 2011Assignee: Emergent Product Development UK LimitedInventors: Robert Graham Feldman, Gordon Dougan, Joseph David Santangelo, David William Holden, Jacqueline Elizabeth Shea, Zoe Hindle
-
Publication number: 20110033501Abstract: The present invention relates to a recombinant bacterium that is capable of eliciting an immune response against at least two enteric pathogens, without substantially inducing an immune response specific to the serotype of the bacterium. The invention also relates to methods of making such a bacterium and vaccines and methods of using such a bacterium.Type: ApplicationFiled: October 6, 2008Publication date: February 10, 2011Applicant: The Arizona Board of Regents for and on behalf of Arizona State UniversityInventors: Roy Curtiss iii, Melha Mellata, Bereket Zekarias, Zhaoxing Shi, Christine Branger, Kenneth Roland
-
Publication number: 20110027309Abstract: Provided herein are Salmonella enteritidis 13A strains and compositions comprising these strains. Also provided are methods of enhancing an immune response against Influenza A and methods of reducing morbidity associated with an Influenza A infection. Methods of enhancing an immune response to a vaccine vector by expressing a polypeptide of CD 154 capable of binding CD40 are also disclosed. Methods of developing a bacterial vaccine vector are disclosed. Methods of generating scarless site-specific mutations in a bacterium are also disclosed.Type: ApplicationFiled: September 18, 2007Publication date: February 3, 2011Inventors: Walter Bottje, Billy Hargis, Luc Berghman, Young Min Kwon, Kimberly Cole, Mandy Cox, Sherryll Layton
-
Patent number: 7871604Abstract: Disclosed is an Environmentally Limited Viability System (ELVS) for microorganisms based on temperature differences between permissive and non-permissive environments. Viability of the microorganisms are limited to the permissive environment by specifically expressing one or more essential genes only in the permissive environment, or expressing one or more lethal genes only in the non-permissive environment. Environmentally Limited Viability Systems are also disclosed involving coordinate expression of a combination of required genes and lethal genes. Microorganisms containing an Environmentally Limited Viability System are useful for release into a permissive environment. Temperature regulated Environmentally Limited Viability Systems are particularly suited for use with recombinant avirulent Salmonella vaccines by limiting their growth to the warmer environment inside the host.Type: GrantFiled: July 22, 1998Date of Patent: January 18, 2011Assignee: Washington UniversityInventors: Roy Curtiss, III, Steven A. Tinge
-
Publication number: 20100330124Abstract: The present invention provides a novel immunogenic composition, vaccine and methods for making and using the immunogenic composition and vaccine. The immunogenic composition is capable of providing an immune response and/or a protective immunity into subjects, preferably mammals, against microorganism-associated disease. The immunogenic composition includes one or more extracellular proteins isolated from a microorganism capable of providing an immune response and/or a protective immunity into subjects against microorganism-associated disease. The isolated extracellular proteins range in molecular weight from about 10,000 Da to about 220,000 Da. Suitable microorganisms may include members of the genus Salmonella, Listeria, Pseudomonas, Staphylococcus, and Vibrio. Kits are also encompassed for detection, diagnosis and prevention of microorganism-associated disease.Type: ApplicationFiled: June 23, 2010Publication date: December 30, 2010Inventor: Richard E. COWART
-
Publication number: 20100285064Abstract: The present invention provides a Withania somnifera fraction rich in withanolides and a vaccine comprising a “Withania somnifera fraction” as an adjuvant.Type: ApplicationFiled: May 5, 2010Publication date: November 11, 2010Applicant: SERUM INSTITUTE OF INDIA LTD.Inventors: Suresh Sakharam Jadhav, Bhushan Patwardhan, Manish Gautam
-
Publication number: 20100284963Abstract: Immunogenic compositions comprising growth regulatable recombinant intracellular pathogens that have been transformed to express recombinant immunogenic antigens of the same or other intracellular pathogens are provided. Exemplary immunogenic compositions include, but are not limited to, growth regulatable and growth limited recombinant intracellular pathogen immunogenic compositions.Type: ApplicationFiled: April 10, 2007Publication date: November 11, 2010Inventors: Marcus A. Horwitz, Michael V. Tullius
-
Publication number: 20100278857Abstract: The present invention provides novel peptides which specifically targets and binds to dendritic cells. Also provided are fusion compositions comprising these peptides and a non-dendritic protein of fragments thereof. Further provided are DNA sequences encoding these peptides and fusion compositions. Methods of using the peptides or fusion compositions to promote an immune responses in an individual via administration also are provided.Type: ApplicationFiled: April 8, 2004Publication date: November 4, 2010Applicant: ADMINISTRATORS OF THE TULANE EDUCATIONAL FUNDInventors: Mansour Mohamadzadeh, Tyler J. Curiel, Cindy A. Morris
-
Publication number: 20100272758Abstract: The present invention provides non-toxic Gram-negative bacteria. In particular, the present invention provides viable Gram-negative bacteria (e.g., E. coli) substantially lacking lipopolysaccharide (LPS, endotoxin) within the outer membrane. The present invention further provides methods of generating viable non-toxic Gram-negative bacteria and uses thereof. The present invention also provides compositions and methods for inducing immune responses and for researching and developing therapeutic agents.Type: ApplicationFiled: January 19, 2007Publication date: October 28, 2010Applicant: Regents of the University of MichiganInventors: Ronald Wesley Woodard, Timothy Charles Meredith, Parag Aggarwal
-
Publication number: 20100260794Abstract: The present invention relates to attenuated guaB deletion mutants of a bacterium infecting veterinary species, more in particular Salmonella enterica, to their use and production. The present invention further relates to live attenuated vaccines based on such mutants for preventing bacterial infections, and more in particular Salmonellosis, in a veterinary species, more in particular poultry.Type: ApplicationFiled: March 20, 2006Publication date: October 14, 2010Inventors: Henri Marcel Jozef De Greve, Connie Theresia Adriaensen, Jean-Pierre Ernest Clement Hernalsteens
-
Publication number: 20100255036Abstract: The invention provides an attenuated enterobacterium comprising an attenuating mutation in the fnr gene, and optionally further comprising a heterologous nucleic acid encoding a foreign antigen. Also provided are pharmaceutical formulations comprising the attenuated enterobacteria of the invention. Further disclosed are methods of inducing an immune response in a subject by administration of an immunogenically effective amount of an attenuated enterobacterium or pharmaceutical formulation of the invention.Type: ApplicationFiled: July 9, 2009Publication date: October 7, 2010Inventors: Hosni M. Hassan, Ryan C. Fink, Matthew R. Evans
-
Patent number: 7807139Abstract: The present invention provides a method for the treatment and/or prevention of bacterial infection caused by Klebsiella pneumoniae and other gram-negative bacteria in central nervous system and/or peripheral blood circulation in a mammal by administering effective amount of outer membrane protein A (OmpA) or its derivatives to a mammal. Also provided are a method for vaccinating a mammal to produce an antibody against bacterial infection caused by Enterobacteriaceae family in central nervous system and/or peripheral blood circulation and a method of detecting or diagnosing bacterial infections caused by Enterobacteriaceae family in central nervous system and/or peripheral blood circulation in a mammal.Type: GrantFiled: January 23, 2009Date of Patent: October 5, 2010Assignee: Taipei Medical UniversityInventors: Yi-Yuan Yang, Hsueh-Hsia Wu, Sy-Jye Leu, Neng-Yao Shih, I-Jen Huang, Ching-Yu Lin, Wen-Shyang Hsieh, Ko-Jiunn Liu, Shih-Yi Huang, Yueh-Lun Lee, Chi-Hsin Lee, Yuan-Soon Ho, Shih-Lan Hsu
-
Publication number: 20100247537Abstract: Adjuvant combinations comprising at least one NKT activator, such as alpha-galactosylceramide (?-Gal-Cer) or iGb3, a CD40 agonist and optionally an antigen are disclosed. The use of these immune adjuvants for treatment of various chronic diseases such as cancers is also provided.Type: ApplicationFiled: April 25, 2008Publication date: September 30, 2010Inventors: Cory Ahonen, Randolph Noelle
-
Patent number: 7790183Abstract: This invention relates to a method for coating a medical device comprising the steps of applying to at least a portion of the surface of said medical device, an antimicrobial coating layer and a non-pathogenic bacterial coating layer, wherein the antimicrobial and non-pathogenic bacterial coating layers inhibit the growth of pathogenic bacterial and fungal organisms. The non-pathogenic bacterium used in the bacterial coating layer is resistant to the antimicrobial agent. Furthermore, the non-pathogenic bacterium layer includes at least one of the following: viable whole cells, non-viable whole cells, or cellular structures or extracts. The antimicrobial agent and non-pathogenic bacterium are used to develop a kit comprising these compositions in one container or in separate containers. The kit is used to coat a catheter prior to implantation in a mammal.Type: GrantFiled: February 26, 2004Date of Patent: September 7, 2010Assignee: Baylor College of MedicineInventors: Rabih O. Darouiche, Richard Hull
-
Publication number: 20100215679Abstract: The disclosure provides an antigenic composition useful for immunization against tularemia. The disclosure provides a method for producing a vaccine for preventing tularemia in humans and animals, a new vaccine against tularemia in humans and animals, and a new approach to producing vaccines against tularemia.Type: ApplicationFiled: October 22, 2007Publication date: August 26, 2010Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Marcus A. Horwitz, Qingmei Jia, Bai-Yu L. Clemens, Daniel Clemens
-
Patent number: 7780966Abstract: An artificial invasin complex is prepared from purified or recombinantly prepared invasins and gram negative bacteria lipopolysaccharides. Typically, IpaB is mixed with IpaC to form a IpaB:IpaC complex. This invasin protein complex is then mixed with the lipopolysaccharide to form an artificial invasin complex. Additional bioactive molecules can be incorporated into the complex during manufacture. This artificial invasin complex is similar in function to native Invaplex 24 or Invaplex 50. The artificial invasin complex has superior immunogenicity properties relative to the native complex and can be tailor made. Its method of preparation lends itself to scale up. The artificial invasin complex can facilitate transport of biomolecules, therapeutics and antibiotics across cell membranes in a manner similar to native Shigella Invaplex.Type: GrantFiled: March 27, 2007Date of Patent: August 24, 2010Assignee: The United States of America as represented by the Secretary of the ArmyInventors: Edwin V. Oaks, Kevin R. Turbyfill, Robert W. Kaminski
-
Publication number: 20100196416Abstract: A typhoid vaccine using heat shock protein (Hsp) of Salmonella typhi and a method for the manufacture thereof. A method of administering a composition comprising an effective amount of a complex consisting of a Hsp, in part or whole, either alone or covalently or non-covalently bound to an antigenic molecule, which when administered elicits specific immunological responses in the host is also describe. The Antigenic molecule refers to the exogenous antigens/immunogens viz LPS, peptide, nucleic acid or polysaccharide or antigenic/immunogenic fragments and derivatives thereof.Type: ApplicationFiled: October 4, 2006Publication date: August 5, 2010Inventors: Mustoori Sairam, Anju Bansal, Sarada S. Surya Kumari, Piyush Paliwal
-
Patent number: 7754227Abstract: This invention relates to conjugates of the Vi polysaccharide of S. typhi with the carrier Pseudomonas aeruginosa recombinant exoprotein A (rEPA), and compositions thereof, and to methods of using of these conjugates and/or compositions thereof for eliciting an immunogenic response in humans, including responses which provide protection against, or reduce the severity of, S. typhi bacterial infections. The conjugates, and compositions thereof, are useful as vaccines to induce serum antibodies against S. typhi and are useful to prevent and/or treat illnesses caused by S. typhi.Type: GrantFiled: March 20, 2007Date of Patent: July 13, 2010Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Zuzana Kossaczka, Shousun Chen Szu, John B. Robbins, Rachel Schneerson, Joseph Shiloach
-
Publication number: 20100136058Abstract: A DNA vaccine suitable for eliciting an immune response against cancer cells comprises a polynucleotide construct operably encoding an a Fra-1 protein, such as a polyubiquitinated human Fra-1 protein, and IL-18, such as human IL-18, in a pharmaceutically acceptable carrier. In a preferred embodiment, the polynucleotide construct is operably incorporated in an attenuated bacterial vector, such as an attenuated Salmonella typhimurium, particularly a doubly attenuated aroA- dam- S. typhimurium. Transformed host cells, methods of inhibiting tumor growth, of vaccinating a patient against cancer, and of delivering genetic material to a mammalian cell in vivo are also described.Type: ApplicationFiled: August 4, 2009Publication date: June 3, 2010Inventors: Yunping Luo, Rong Xiang, Ralph A. Reisfeld
-
Publication number: 20100136060Abstract: The present invention relates to the use of an immunogenic composition that comprises a salmonella antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV2 infection, even more preferably PCVAD. The use relates to a method comprising the steps of administering the composition to an animal in need thereof, preferably prior to disease exposure. Administration of salmonella antigen, preferably a salmonella vaccine, lessens the incidence and reduces the severity of PCVAD.Type: ApplicationFiled: November 21, 2007Publication date: June 3, 2010Applicant: BOEHRINGER INGELHEIM VETMEDICA, INC.Inventor: John Kolb
-
Publication number: 20100062019Abstract: The present invention provides for a novel oil-in-water (O/W) emulsion, with increased stability in the presence of bacterial or viral suspensions, especially those concentrated and non-purified or weakly purified. The emulsion of the present invention can act as vehicle for the delivery of a pharmaceutical composition comprising at least one immunogen and, in particular, an immunogen selected from the group comprising an inactivated pathogen, an attenuated pathogen, a subunit, a recombinant expression vector, and a plasmid or combinations thereof.Type: ApplicationFiled: September 10, 2009Publication date: March 11, 2010Inventors: Alexis Guy Andre Parisot, Stephanie Marie-Catherine Desgouilles-Blechet, Catherine Charreyre
-
Patent number: 7674467Abstract: The present invention is directed to isolated Salmonella bacteriophage, and methods of using Salmonella bacteriophage, or polynucleotides and polypeptides derived therefrom, to control the growth or contamination of food products by Salmonella. The present invention also contemplates the use of Salmonella bacteriophage, and polynucleotides and polypeptides derived therefrom, for the treatment of host infections or environmental contamination by Salmonella.Type: GrantFiled: September 3, 2004Date of Patent: March 9, 2010Assignee: Intralytix, Inc.Inventors: Alexander Sulakvelidze, Shanmuga Sozhamamnnan, Gary R. Pasternack
-
Patent number: 7655241Abstract: The present invention concerns the use of methods and compositions to prophylactically or therapeutically vaccinate a subject against a pathogen or disease. Embodiments of the invention include the production of an attenuated bacterium from the family Enterobacteriaceae with a non-functional lipoprotein for use as a vaccine or as a vaccine vector for delivering antigens to a subject to be vaccinated. In certain embodiments, a bacterium of the Enterobacteriaceae family lacking a wild type LP, for example Salmonella typhimurium lacking a wild type LP, may be produced and used as a vaccine or vaccine vector.Type: GrantFiled: March 20, 2003Date of Patent: February 2, 2010Assignee: The Board of Regents of the University of Texas SystemInventors: Gary R. Klimpel, David W. Niesel, Ashok Chopra, Jian Sha
-
Publication number: 20100003284Abstract: A live attenuated bacterium of the genus Escherichia, Salmonella or Yersinia, said bacterium being incapable of expressing a functional Eda protein as a result of a mutation in the eda gene and a vaccine comprising the live attenuated bacterium.Type: ApplicationFiled: August 26, 2004Publication date: January 7, 2010Applicant: THE BOARD OF GOVERNORS FOR HIGHER EDUCATION, STATE OF PHODE ISLAND AND PROVIDENCE PLANTATIONSInventor: Paul S. Cohen
-
Publication number: 20090324642Abstract: A method for eliciting or inducing an immune response in a human or animal subject, comprises administering to said subject a composition comprising an antigen and an adjuvant, wherein the composition is administered to the subject by the intra-lung route.Type: ApplicationFiled: August 31, 2007Publication date: December 31, 2009Inventors: Stirling John Edwards, Martin John Pearse, Jean-Pierre Yves Scheerlinck, Philip Sutton
-
Publication number: 20090297561Abstract: The invention provides methods of generating phage lysate bacterins, as well as phage lysate bacterin compositions. The invention further encompasses methods of vaccination comprising administering phage lysate bacterin to an animal in need thereof. The invention further encompasses methods of reducing infection or colonization of poultry or poultry eggs using phage bacterin lysates. Method of vaccination comprising administering to an animal in need of immunization an amount of phage lysate bacterin to induce an immune response.Type: ApplicationFiled: September 3, 2004Publication date: December 3, 2009Applicant: IntralytixInventors: Gary R. Pasternack, Alexander Sulakvelidze, Torrey Brown
-
Publication number: 20090280145Abstract: The present invention relates to an immunogen-carrier having immunopotentiating or adjuvant properties. More particularly, the immunogen-carrier is a virus-like particle (VLP) from the family of potexvirus, and most particularly the papaya mosaic virus. The VLP produced by recombinant techniques is in fusion with one of its own proteins a protein immunogen. The above VLP and a protein or a protein extract from a viral, bacterial or parasital pathogen may be used as a vaccine.Type: ApplicationFiled: April 3, 2009Publication date: November 12, 2009Inventors: Denis Leclerc, Constantino Roberto Lopez-Macias
-
Patent number: 7608247Abstract: The present invention provides a method for the treatment and/or prevention of bacterial infection in central nervous system and/or peripheral blood circulation in a mammal by administering effective amount of outer membrane protein A (OmpA) or its derivatives to a mammal. Also provided is an antibody binding to OmpA that can assay OmpA levels in a biological sample and detect or diagnose bacterial infection in central nervous system and/or peripheral blood circulation.Type: GrantFiled: March 11, 2008Date of Patent: October 27, 2009Assignee: Taipei Medical UniversityInventors: Yi-Yuan Yang, Hsueh-Hsia Wu, Sy-Jye Leu, I-Jen Huang, Neng-Yao Shih, Ko-Jiunn Liu, Mei-Ru Chen, Wen-Shyang Hsieh, Chi-Hsin Lee
-
Publication number: 20090263419Abstract: A live, attenuated bacterium of the genus Escherichia, Yersinia or Salmonella, that does not have a functional tRNA5leu, and vaccines comprising the live, attenuated bacterium.Type: ApplicationFiled: May 21, 2009Publication date: October 22, 2009Applicant: The Board of Governers for Higher Education, State of Rhode Island and Providence PlantationsInventor: Paul S. Cohen
-
Publication number: 20090232852Abstract: The present invention provides a method for the treatment and/or prevention of bacterial infection caused by klebsiella pneumoniae and other gram-negative bacteria in central nervous system and/or peripheral blood circulation in a mammal by administering effective amount of outer membrane protein A (OmpA) or its derivatives to a mammal. Also provided are a method for vaccinating a mammal to produce an antibody against bacterial infection caused by Enterobacteriaceae family in central nervous system and/or peripheral blood circulation and a method of detecting or diagnosing bacterial infections caused by Enterobacteriaceae family in central nervous system and/or peripheral blood circulation in a mammal.Type: ApplicationFiled: January 23, 2009Publication date: September 17, 2009Applicant: Taipei Medical UniversityInventors: Yi-Yuan Yang, Hsueh-Hsia Wu, Sy-Jye Leu, Neng-Yao Shih, I-Jen Huang, Ching-Yu Lin, Wen-Shyang Hsieh, Ko-Jiunn Liu, Shih-Yi Huang, Yueh-Lun Lee, Chi-Hsin Lee, Yuan-Soon Ho, Shih-Lan Hsu
-
Publication number: 20090208534Abstract: The invention relates to an attenuated Salmonella sp. that is capable of targeting a solid tumor when administered in vivo comprising a short hairpin (sh) RNA construct, and methods of inhibiting the growth or reducing the volume of a solid tumor cancer comprising administering an effective amount of an attenuated Salmonella sp. to a patient having a solid tumor cancer, wherein said attenuated Salmonella sp. is a tumor targeting attenuated Salmonella sp. expressing a short hairpin (sh) RNA which attenuated Salmonella sp. is capable of inhibiting the growth or reducing the volume of the solid tumor cancer when administered in vivo.Type: ApplicationFiled: July 24, 2007Publication date: August 20, 2009Applicant: The Government of The United States of America, as represented by the Secretary, Dept.of HealthInventors: Deqi Xu, Dennis J. Kopecko, Jiadi Hu, Ling Zhang, Xuejian Zhao, Lifang Gao
-
Publication number: 20090181054Abstract: The present invention describes derivatized polysaccharide-protein conjugates, a composition comprising one or more of such derivatized polysaccharide-protein conjugates and methods of immunizing human patients with the same. The derivatized polysaccharide-protein conjugates are purified capsular polysaccharides from Neisseria meningitidis serogroups A, C, W-135, and Y, derivatized chemically activated and selectively attached to a carrier protein by means of a covalent chemical bond, forming polysaccharide-protein conjugates capable of eliciting long-lasting immunity to a variety of N. meningitidis strains.Type: ApplicationFiled: March 2, 2009Publication date: July 16, 2009Inventor: Robert P. Ryall
-
Publication number: 20090175913Abstract: The invention concerns novel Salmonella enterica attenuated strains, characterized in that they are inactivated at the level of the znuABC operon through mutation in at least one of the znuA, znuB, znuC genes of such operon, for uses in medical or veterinary fields as vaccines.Type: ApplicationFiled: June 8, 2007Publication date: July 9, 2009Inventors: Serena Ammendola, Andrea Battistoni, Paolo Pasquali
-
Publication number: 20090162402Abstract: The present invention provides compositions including siderophore receptor polypeptides and porins from gram negative microbes, and preferably, lipopolysaccarhide at a concentration of no greater than about 10.0 endotoxin units per milliliter. The present invention also provides methods of making and methods of using such compositions.Type: ApplicationFiled: February 26, 2009Publication date: June 25, 2009Applicant: Epitopix, LLCInventors: Daryll A. Emery, Darren E. Straub, Donavan E. Zammert, Gayla K. Kallevig
-
Patent number: 7541043Abstract: Compositions and methods for protecting a susceptable host against an infection of Shigella sonnei are disclosed. Such compositions and methods are useful for protecting the host against bacillary dysentery and shigellosis.Type: GrantFiled: January 15, 2003Date of Patent: June 2, 2009Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Dennis J. Kopecko, De-Qi Xu, John O. Cisar
-
Publication number: 20090136623Abstract: The present invention relates to growth-inhibitory composition against pathogenic bacteria of meat based food stuff comprising IgY, a specific immunoglobulin derived from yolk of egg. The 12 representative bacteria and other microbes deteriorating quality of process meat products that the IgY of the present invention targets include Aeromonas hydrophila, Bacilluis cereus, Campylobacter jejuni, Clostridium perfringens, 0157: H7 (Escherichia coli 0157:H7), Lactobacillus, Listeria monocytogens, Sacromyces cerevisae, Salmonella enteritidis, Salmonella typhimurium, Staphylococcus aureus, and Staphylococcus epidermidis. As the form of antigen, the 12 bacteria are injected to chickens separately to obtain IgY of the present invention against the 12 pathogens.Type: ApplicationFiled: March 12, 2007Publication date: May 28, 2009Inventor: Min-Seok SONG
-
Publication number: 20090123500Abstract: The invention provides a vaccine for immunizing poultry and other animals against infection by a gram-negative bacteria, and a method of immunizing an animal using the vaccine. The vaccine may contain purified siderophore receptor proteins derived from a single strain or species of gram-negative bacteria or other organism, which are cross-reactive with siderophores produced by two or more strains, species or genera of gram-negative bacteria. The invention further provides a process for isolating and purifying the siderophore receptor proteins, and for preparing a vaccine containing the proteins. Also provided is a method for diagnosing gram-negative sepsis.Type: ApplicationFiled: December 31, 2008Publication date: May 14, 2009Applicant: Epitopix, LLCInventors: Daryll A. Emery, Darren E. Straub
-
Patent number: 7514089Abstract: The present invention is directed to mutant Salmonella sp. having a genetically modified msbB gene in which the mutant Salmonella is capable of targeting solid tumors. The present invention further relates to the therapeutic use of the mutant Salmonella for growth inhibition and/or reduction in volume of solid tumors.Type: GrantFiled: April 28, 2005Date of Patent: April 7, 2009Assignee: Vion Pharmaceuticals, Inc.Inventors: David Bermudes, Kenneth Brooks Low
-
Publication number: 20090081257Abstract: The present disclosure describes pathogenic bacteria that have been modified to be deficient in NiFe hydrogenase activity; compositions comprising such modified bacteria, and the use of such bacteria to protect animals from pathogenic enteric bacterial infections.Type: ApplicationFiled: February 28, 2005Publication date: March 26, 2009Inventors: Robert J. Maier, John S. Gunn
-
Publication number: 20090017073Abstract: A method for modulating Nod1 activity wherein said method comprises the steps of providing cells expressing a functional Nod1: and bringing said cells into contact with a molecule related to compositions comprising a molecule related to MTP and use of a molecule related to MTP for modulating inflammation and/or apoptosis.Type: ApplicationFiled: June 5, 2008Publication date: January 15, 2009Inventors: Philippe Sansonetti, Stephen Girardin, Dana Philpott, Ivo Boneca
-
Publication number: 20090010964Abstract: The invention provides for a method of enhancing immunological responses to an antigen in a vaccine formulation, and for a vaccine formulation that provides for an enhanced immunological response to an antigen. In the method and formulation the antigen is administered with an adjuvant which adjuvant comprises a solution of nitrous oxide gas in a pharmaceutically acceptable carrier solvent for the gas and which adjuvant includes at least one fatty acid or ester or other suitable derivative thereof selected from the group consisting of oleic acid, linoleic acid, alpha-linolenic acid, gamma-linolenic acid, arachidonic acid, eicosapentaenoic acid [C20: 5?3], decosahexaenoic acid [C22: 6?3], ricinoleic acid and derivatives thereof selected from the group consisting of the C1 to C6 alkyl esters thereof, the glycerol-polyethylene glycol esters thereof and the reaction product of hydrogenated natural oils composed largely of ricinoleic acid based oils, such as castor oil with ethylene oxide.Type: ApplicationFiled: August 3, 2006Publication date: January 8, 2009Inventors: Anne Grobler, Abraham Frederik Kotze
-
Publication number: 20080311156Abstract: The present invention relates to adjuvant compositions which are suitable to be used in vaccines. In particular, the adjuvant compositions of the present invention comprises a saponin and an immunostimulatory oligonucleotide, optionally with a carrier. Also provided by the present invention are vaccines comprising the adjuvants of the present invention and an antigen. Further provided are methods of manufacture of the adjuvants and vaccines of the present invention and their use as medicaments. Methods of treating an individual susceptible to or suffering from a disease by the administration of the vaccines of the present invention are also provided.Type: ApplicationFiled: July 11, 2008Publication date: December 18, 2008Inventors: Martin FRIEDE, Nathalie Garcon, Catherine Marie Ghislaine Gerard, Philippe Hermand
-
Publication number: 20080260776Abstract: The present invention relates to a pharmaceutical composition providing protective unity against a broad spectrum of Salmonella enterica serovars.Type: ApplicationFiled: May 17, 2005Publication date: October 23, 2008Inventors: Dirk Bumann, Heiko Apfel
-
Publication number: 20080260783Abstract: An antigen composition for stimulating an immune response in an inoculated avian species to at least one intestinal pathogenic organism includes naturally-occurring wild Salmonella enterica subspecies in O-serogroups B, C2 and D. Subspecies in O-serogroup B can include Salmonella typhimurium and/or Salmonella agona. Subspecies in O-serogroup C2 can include Salmonella Kentucky. Subspecies in O-serogroup D can include Salmonella enteritidis. The antigen composition can be used alone or in combination with a Marek's Disease vaccine to reduce shedding of E. coli and/or Salmonella bacteria.Type: ApplicationFiled: February 4, 2008Publication date: October 23, 2008Inventor: Konky SOTOMAYOR
-
Publication number: 20080248066Abstract: Free-living microbes are provided in which the nucleic acid has been modified so that the microbe is attenuated for proliferation and/or which comprise genetic mutations that attenuate the ability of the microbe to repair its nucleic acid. Methods of using the modified microbes for the loading, activation, and/or maturation of antigen-presenting cells are also provided. Vaccine compositions comprising the modified microbes and/or the antigen-presenting cells and methods of using the vaccines are also provided. The microbes may be further modified to include heterologous antigens, such as tumor antigens or infectious disease antigens, for use as a vaccine against cancer or infectious diseases.Type: ApplicationFiled: August 11, 2006Publication date: October 9, 2008Applicant: Cerus CorporationInventors: Thomas W. Dubensky, Dirk G. Brockstedt, Keith S. Bahjat, John E. Hearst, David N. Cook, William S. Luckett
-
Publication number: 20080220022Abstract: The present invention relates to the field of vaccination against Salmonella in animals, particularly avian animals. The present invention also encompasses kits and uses of Salmonella immunogenic compositions or vaccines. The present invention further relates to methods and compositions comprising at least one primo-administration of an attenuated immunogenic composition or vaccine, comprising a pharmaceutically or veterinarily acceptable excipient, diluent or vehicle and at least one attenuated Salmonella, administered to an avian animal before at least one boost-administration of an inactivated immunogenic composition or vaccine, comprising a pharmaceutically or veterinarily acceptable excipient, diluent or vehicle, and at least one inactivated Salmonella.Type: ApplicationFiled: December 10, 2007Publication date: September 11, 2008Inventors: Francois-Xavier Le Gros, Stephane Lemiere